Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-679/ECHO-302: Pembrolizumab plus epacadostat vs sunitinib or pazopanib in first-line metastatic renal cell carcinoma
2024-512016-22-00Phase 3Completed
- Sponsor
- Incyte
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial in clear cell renal cell carcinoma (ccRCC) comparing Pembrolizumab + epacadostat with Standard-of-care (sunitinib or pazopanib) (2 arms). Primary endpoint: Objective Response Rate (ORR) of Pembrolizumab + Epacadostat Versus Standard of Care (SOC). Started Apr 2024; status: completed.
02
Drugs
pembrolizumabepacadostat
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2024-512016-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512016-22-00.